Trial Profile

A Phase 2, Open-label, Single Arm, Exploratory, Observational Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 May 2019 According to a ProMetic Life Sciences media release, data from a post-hoc analysis of this trial were presented at the American Thoracic Society (ATS) 2019 International Conference.
12 Dec 2018 Results assessing safety, efficacy and pharmacokinetics published in the European Respiratory Journal.
23 May 2018 Results assessing the effect of PBI-4050 alone or in combination with pirfenidone or nintedanib on blood biomarkers linked to the fibrotic process presented at the 114th International Conference of the American Thoracic Society.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com